MYCN and neoplasm: Clinically more relevant BET inhibitors have been tested in several clinical trials of adult cancers (NCT02391480 (Drug: ABBV-075), NCT03068351 (Drug: RO6870810), NCT02158858 (Drug: CPI-0610) and NCT02419417 (Drug: BMS-986158)) and OTX015 (NCT02698189), which has been shown to be effective against mouse and human MYCN-driven tumor models [92].